1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,250 | 9,550 | 03.10. | |
| 0,000 | 0,000 | 03.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Inducement Grants | 99 | GlobeNewswire (Europe) | BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies... ► Artikel lesen | |
| ELICIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.09. | Elicio Reports Strong T Cell Responses In Phase 2 Trial Of Cancer Vaccine | 1 | RTTNews | ||
| 17.09. | Elicio: Krebsimpfstoff ELI-002 löst bei 99 % der Patienten starke Immunantwort aus | 2 | Investing.com Deutsch | ||
| 17.09. | Elicio's cancer vaccine ELI-002 shows strong immune response in 99% of patients | 2 | Investing.com | ||
| 17.09. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial | 106 | GlobeNewswire (Europe) | ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed... ► Artikel lesen | |
| 12.08. | Elicio Therapeutics Inc.: Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease ("MRD") Positive, Adjuvant-Stage Patients | 147 | GlobeNewswire (Europe) | At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS... ► Artikel lesen | |
| 12.08. | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.08. | Elicio Therapeutics GAAP EPS of -$0.66 | 2 | Seeking Alpha | ||
| 07.08. | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Elicio Therapeutics Inc.: Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates | 256 | GlobeNewswire (Europe) | Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven... ► Artikel lesen | |
| 05.08. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Studienausblick beflügelt: H.C. Wainwright hebt Kursziel für Elicio Therapeutics an | 1 | Investing.com Deutsch | ||
| 17.06. | Elicio Therapeutics Inc.: Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer | 2 | GlobeNewswire (USA) | ||
| 04.06. | Elicio secures $10 million to extend cash runway | 1 | Investing.com | ||
| 04.06. | Elicio Therapeutics Inc.: Elicio Therapeutics Secures $10 Million in Financing | 1 | GlobeNewswire (USA) | ||
| 04.06. | Elicio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Elicio Therapeutics GAAP EPS of -$0.87 | 2 | Seeking Alpha | ||
| 13.05. | Elicio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | Elicio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,775 | +2,31 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| OCUGEN | 1,524 | +0,73 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,800 | -0,46 % | Viking Therapeutics: Bald wieder im Rampenlicht? | Die Aktionäre von Viking Therapeutics mussten zuletzt einen herben Kursrückgang verkraften, während ein potenzieller Konkurrent für eine hohe Milliardenbewertung übernommen wurde. Dabei gilt Viking... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,060 | -3,74 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,142 | -0,10 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| VAXART | 0,350 | +28,11 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| IBIO | 0,705 | -2,76 % | iBio, Inc.: iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,930 | -13,06 % | RedHill Biopharma stock surges after court upholds $10M judgment | ||
| ARBUTUS BIOPHARMA | 3,770 | +2,28 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,782 | -4,30 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| ALDEYRA | 4,436 | -6,65 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MANNKIND | 4,950 | +0,06 % | MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer | WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products... ► Artikel lesen | |
| TRAWS PHARMA | 2,225 | +22,25 % | Traws Pharma, Inc.: Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 | Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,371 | -0,44 % | Coherus Oncology: Nach der Rallye folgt der Durchbruch? | Die Aktie von Coherus Oncology hat in den vergangenen Monaten deutlich an Dynamik gewonnen. Mit über 60 Prozent Kursplus seit April 2025 rückt das Unternehmen ins Rampenlicht - getragen von wachsenden... ► Artikel lesen |
ELICIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,100 (+1,10 %) liegt der Kurs bei 9,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICIO THERAPEUTICS INC finden Sie auf Wallstreet Online.